Abiomed (ABMD) Tops Q4 EPS by 5c

Abiomed (NASDAQ: ABMD) reported Q4 EPS of $0.40, $0.05 better than the analyst estimate of $0.35. Revenue for the quarter came in at $124.7 million versus the consensus estimate of $122.5 million.

The Company is giving its fiscal year 2018 guidance for total revenues to be in the range of $555 million to $575 million, an increase of 25% - 29% over the prior year. The Company is also giving its fiscal year 2018 guidance for GAAP operating margin to be in the range of 22% to 24%.

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c